Lantheus Holdings shares climb on strong earnings and FDA approvals, as a potential $7 billion acquisition bid from Curium Pharma draws significant market attention to the diagnostic firm.
Lantheus rallied on strong quarterly earnings, FDA approval of PYLARIFY TruVu, and a potential $7 billion takeover bid from Curium Pharma.
Lantheus Holdings (LNTH) shares surged 92% over the past year, driven by robust quarterly earnings and the FDA approval of PYLARIFY TruVu. The diagnostic firm is currently the subject of intense M&A speculation, with reports of a potential $7 billion takeover bid from Curium Pharma fueling investor optimism in the radiopharmaceutical sector.
Lantheus is benefiting from strong quarterly earnings, the FDA approval of PYLARIFY TruVu, and market speculation regarding a potential $7 billion acquisition by Curium Pharma.